The World Health Organization approved the emergency use of Sinovac's COVID-19 vaccine on Tuesday.
It's the second Chinese vaccine to be given the green light by the WHO after Sinopharm last month.
The emergency listing is a signal to national regulators of a product's safety and efficacy.
Results showed Sinovac's Coronavac prevented symptomatic disease in more than half of those vaccinated and prevented severe COVID-19 in 100% of the studied population.
WHO director Tedros Adhanom Ghebreyesus welcomed the vaccine's approval.
"The easy storage requirements of Coronavac, make it very suitable for low resource settings. It is now the eighth vaccine to receive EUL by WHO. It's now crucial to get these life-saving tools to the people that need them quickly."
The emergency listing allows for the vaccine to now be included in COVAX.
That's the global program providing vaccines mainly to poor countries struggling with vaccine supplies.
The WHO's endorsement is a major boost for Sinovac after earlier data in clinical trials showed a wide range of efficacy rates.
As of the end of May, Sinovac said it had already supplied more than 600 million doses of its vaccine at home and abroad.
Many of the doses have gone to countries in Africa, Latin America and Asia.